Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIKTAC pilot study of daratumumab + carfilzomib + pomalidomide + dexamethasone for multiple myeloma with acute renal failure
2024-514702-31-00Phase 2Authorised
- Sponsor
- Medical University of Innsbruck
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Medical University of Innsbruck. Primary endpoints: Dialysis independence rate after induction and Renal function improvement after induction. Planned start Oct 2024; status: authorised.
02
Drugs
daratumumabcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514702-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514702-31-00.